These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11176224)

  • 1. Homocysteine and stroke.
    Hankey GJ; Eikelboom JW
    Curr Opin Neurol; 2001 Feb; 14(1):95-102. PubMed ID: 11176224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homocysteine and risk of stroke.
    Perry IJ
    J Cardiovasc Risk; 1999 Aug; 6(4):235-40. PubMed ID: 10501275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homocysteine and cerebral ischemia: pathogenic and therapeutical implications.
    Pezzini A; Del Zotto E; Padovani A
    Curr Med Chem; 2007; 14(3):249-63. PubMed ID: 17305530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.
    Toole JF; Malinow MR; Chambless LE; Spence JD; Pettigrew LC; Howard VJ; Sides EG; Wang CH; Stampfer M
    JAMA; 2004 Feb; 291(5):565-75. PubMed ID: 14762035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke.
    VITATOPS Trial Study Group
    Cerebrovasc Dis; 2002; 13(2):120-6. PubMed ID: 11867886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homocysteine levels in patients with stroke: clinical relevance and therapeutic implications.
    Hankey GJ; Eikelboom JW
    CNS Drugs; 2001; 15(6):437-43. PubMed ID: 11524022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The China Stroke Secondary Prevention Trial (CSSPT) protocol: a double-blinded, randomized, controlled trial of combined folic acid and B vitamins for secondary prevention of stroke.
    Liu X; Shi M; Xia F; Han J; Liu Z; Wang B; Yang F; Li L; Wu S; Wang L; Liu N; Lv Y; Zhao G
    Int J Stroke; 2015 Feb; 10(2):264-8. PubMed ID: 23490255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between homocysteine and endothelial dysfunction markers in stroke disease.
    Abdulle AM; Pathan JY; Moussa N; Gariballa S
    Nutr Neurosci; 2010 Feb; 13(1):2-6. PubMed ID: 20132648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine and stroke prevention: have the trials settled the issue?
    Spence JD
    Int J Stroke; 2006 Nov; 1(4):242-4. PubMed ID: 18706027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of homocysteine, C-reactive protein and cardiovascular disease in patients with renal disease.
    Eikelboom JW; Hankey GJ
    Curr Opin Nephrol Hypertens; 2001 May; 10(3):377-83. PubMed ID: 11342801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained homocysteine-lowering effect over time of folic acid-based multivitamin therapy in stroke patients despite increasing folate status in the population.
    Hankey GJ; Eikelboom JW; Loh K; Tang M; Pizzi J; Thom J; Yi Q
    Cerebrovasc Dis; 2005; 19(2):110-6. PubMed ID: 15608435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homocysteine, B-vitamin supplementation, and stroke prevention: from observational to interventional trials.
    Schwammenthal Y; Tanne D
    Lancet Neurol; 2004 Aug; 3(8):493-5. PubMed ID: 15261610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Folate, vitamin B12, and risk of ischemic and hemorrhagic stroke: a prospective, nested case-referent study of plasma concentrations and dietary intake.
    Van Guelpen B; Hultdin J; Johansson I; Stegmayr B; Hallmans G; Nilsson TK; Weinehall L; Witthöft C; Palmqvist R; Winkvist A
    Stroke; 2005 Jul; 36(7):1426-31. PubMed ID: 15933256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of total homocysteine-lowering drugs on cardiovascular disease.
    Sunder-Plassmann G; Winkelmayer WC; Födinger M
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2637-51. PubMed ID: 11060826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homocysteine, hypertension and stroke.
    Perry IJ
    J Hum Hypertens; 1999 May; 13(5):289-93. PubMed ID: 10376845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial.
    Dusitanond P; Eikelboom JW; Hankey GJ; Thom J; Gilmore G; Loh K; Yi Q; Klijn CJ; Langton P; van Bockxmeer FM; Baker R; Jamrozik K
    Stroke; 2005 Jan; 36(1):144-6. PubMed ID: 15569860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aetiology and treatment of hyperhomocysteinaemia causing ischaemic stroke.
    Sarkar PK; Lambert LA
    Int J Clin Pract; 2001 May; 55(4):262-8. PubMed ID: 11406912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteine-lowering trials for prevention of heart disease and stroke.
    Clarke R
    Semin Vasc Med; 2005 May; 5(2):215-22. PubMed ID: 16047274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamins and stroke: the homocysteine hypothesis still in doubt.
    Ntaios GC; Savopoulos CG; Chatzinikolaou AC; Kaiafa GD; Hatzitolios A
    Neurologist; 2008 Jan; 14(1):2-4. PubMed ID: 18195649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between smoking and homocysteine concentration in ischemic stroke patients].
    Qiao SD; Liu N; Fan DS; Gao XH; Zhou JW
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(47):3342-4. PubMed ID: 19257965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.